Company Overview and News

 
Trade Talks, Micron's Guidance, & Marijuana Stock Charts | Free Lunch

2018-05-21 zacks
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney covers the latest in the ongoing trade talks between the U.S. and China and highlights why trendy memory-chip maker Micron (MU - Free Report) moved higher this morning. Later, Ryan digs into two key charts from a pair of popular marijuana stocks.

2
FDA names and shames drugmakers to encourage generic competition

2018-05-17 sfgate
Pharmaceutical companies that spend billions to develop drugs do not want competitors to profit from inexpensive generic copies of blockbuster medicines. So they fight for patent extensions, seek new uses for old products and, sometimes, prevent generic drug companies from obtaining samples.

 
Marijuana Constituent Significantly Reduces Severe Epileptic Seizures

2018-05-17 genengnews
The psychotropic effects of cannabis may be what the historically maligned drug is best known for, yet in recent decades a growing body of evidence continues to suggest that the drug has numerous valuable properties that make it a potentially valuable therapeutic. Now, investigators from NYU School of Medicine have shown in a new large-scale, randomized, controlled trial that cannabidiol (CBD)—a compound derived from the cannabis plant that does not produce a "high"—significantly reduces the number of dangerous seizures in patients with a severe form of epilepsy called Lennox-Gastaut syndrome.

 
Cannabis Wheaton Announces Closing of Dosecann Acquisition

2018-05-17 globenewswire
VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX-V:CBW) ("Cannabis Wheaton" or the "Company") is pleased to announce that it has closed its previously announced acquisition (the “Transaction”) of all of the outstanding securities of Dosecann Inc. (“Dosecann”), a late-stage “Licensed Dealer” applicant pursuant to the Narcotic Control Regulations (the “NCR”).

 
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Cannabidiol Oral Solution in Lennox-Gastaut Syndrome

2018-05-16 globenewswire
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy –

 
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut Syndrome

2018-05-16 globenewswire
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy –

 
Zynerba: Transdermal Cannabinoids Have Significant Potential

2018-05-15 seekingalpha
Cannabinoids tend to be lumped together and treated as one "hot topic" despite significant differences that exist among them.

2
GW Pharmaceuticals Stock Slides on Q2 Earnings Miss

2018-05-09 investorplace
GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) stock fell late Tuesday as the company unveiled its latest quarterly earnings results, which missed analysts’ expectations.

 
GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q2 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings and welcome to the GW Pharmaceuticals' Second Quarter 2018 Financial Results Conference Call. At this time all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

 
BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents

2018-05-08 reuters
* GW PHARMACEUTICALS PLC - QTRLY LOSS PER ADS 312.0 CENTS Source text for Eikon: Further company coverage:

 
GW Pharmaceuticals (GWPH) Stock Moving Higher After Posting Q2 Earnings

2018-05-08 zacks
GW Pharmaceuticals PLC (GWPH - Free Report) just released its latest quarterly financial results, posting adjusted earnings of -$3.12 per share and revenues of $3.35 million.

1
GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2018 Health Care Conference

2018-05-08 globenewswire
LONDON and CARLSBAD, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.

4
7 High-Growth, High-Risk Stocks to Invest In Right Now

2018-05-07 investorplace
Perhaps the most important part of choosing investments is determining how much risk you can take on.

 
3 Marijuana ETFs for Everyday Investors to Play the Cannabis Movement

2018-05-07 investorplace
Four years ago, the marijuana legalization movement was firmly underway. Cannabis, both medical and recreational, was on more state ballots than ever before. And though many of those referendums were ultimately rejected, some got the green light. And simply appearing on a ballot at all was a victory for the cannabis industry.

 
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

2018-05-07 zacks
Mylan N.V. (MYL - Free Report) is scheduled to report first-quarter 2018 results on May 9, before the market opens.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...